Abstract | PURPOSE: METHODS: This prospective, multicenter, open-label, randomized trial enrolled 157 patients with chemotherapy-related anemia (Hb <or= 105 g/L, serum ferritin <or= 450 pmol/L or <or= 675 pmol/L with transferrin saturation <or= 19%) receiving subcutaneously rHuEPO 40000 U once weekly to: (1). no- iron; (2). oral iron 325 mg twice daily; (3) iron dextran repeated 100mg IV bolus; or (4) iron dextran total dose infusion (TDI). Hb and quality of life (QOL) were measured at baseline and throughout. RESULTS: All groups showed Hb (P <.0001) increases from baseline. Mean Hb increases for both IV iron groups were greater (P <.02) than for no- iron and oral iron groups. The percentage of patients with hematopoietic responses was higher (P <.01) in both IV iron groups (each case 68%) compared with no- iron (25%) and oral iron (36%) groups. IV iron groups showed increases in energy, activity, and overall QOL from baseline, compared with a decrease in energy and activity for no- iron group and no change in activity or overall QOL for oral iron group. CONCLUSION: rHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia. Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added.
|
Authors | Michael Auerbach, Harold Ballard, J Richard Trout, Marilyn McIlwain, Alan Ackerman, Huzefa Bahrain, Stefan Balan, Lance Barker, Jeevindra Rana |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 22
Issue 7
Pg. 1301-7
(Apr 01 2004)
ISSN: 0732-183X [Print] United States |
PMID | 15051778
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Recombinant Proteins
- Erythropoietin
- Iron-Dextran Complex
- Iron
|
Topics |
- Abnormalities, Drug-Induced
- Administration, Oral
- Aged
- Anemia
(drug therapy, etiology)
- Antineoplastic Agents
(adverse effects)
- Erythropoietin
(therapeutic use)
- Female
- Humans
- Infusions, Intravenous
- Iron
(administration & dosage)
- Iron-Dextran Complex
(administration & dosage)
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Prospective Studies
- Quality of Life
- Recombinant Proteins
|